5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).
5‐ASA may leads to lower withdrawal due to adverse events compared with purine antimetabolites (low certainty).
It is very uncertain whether 5‐ASAs changes withdrawal due to adverse events compared with anti TNF‐ɑ (very low certainty).
It is very uncertain whether sulphasalazine changes withdrawal due to adverse events compared with placebo (very low certainty).
It is very uncertain whether 5‐ASA changes withdrawal due to adverse events compared with no treatment (very low certainty).
Azathioprine or 6‐mercaptopurine may leads to higher withdrawal due to adverse events compared with 5‐aminosalicylic acid (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawal due to adverse events compared with anti TNF‐α (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).